Pacific Edge Limited Ordinary Shares
PEB.NZXHealth Care
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.
Market Data
$0.305
0.0%$378.8M
-8.0x
$-0.038
0.00%
+2.1%
Recent Announcements
D&O Disclosures - Multiple
Multiple Pacific Edge Limited directors and the CEO acquired ordinary shares in June 2026 through a retail offer and placement: Anna Kate Stove increased holdings from 267,100 to 294,552 shares, Sarah Natalie Park from 218,600 to 228,600 shares, Antony George Barclay from 450,000 to 538,235 shares, and CEO Peter Meintjes from 1,291,012 to 2,675,902 shares (plus existing options), with total consideration ranging from $2,000 to $15,000 per director.
SPH Notice - ANZ New Zealand Investments Limited
ANZ New Zealand Investments Limited changed substantial holding from 18.221% to 17.185%.
ASX - 2A - Capital Change
Pacific Edge Limited (PEB) applied for quotation of 69,836,561 ordinary fully paid shares on June 4, 2026, comprising: 62,704,581 shares from a retail offer at NZD 0.17 per share, 470,588 shares issued to professional service providers for capital raising services valued at NZD 80,000, and 6,661,392 shares issued to employees under an incentive scheme in lieu of compensation.
Capital Change Notice - Pacific Edge
Pacific Edge Limited issued 69,836,561 ordinary shares on 4 June 2026 at NZ$0.170 per share, comprising 62.7 million shares via retail offer, 6.7 million shares to employees as performance incentives, and 0.47 million shares for professional services, representing 5.959% of the company's total share class.
PEB Completes Oversubscribed NZ$36.1m Capital Raise
Pacific Edge (NZX/ASX: PEB) completed a NZ$36.1 million capital raising, comprising a NZ$25.4 million placement and a NZ$10.7 million retail offer that was significantly oversubscribed with NZ$46.0 million in applications; 62.7 million new shares will be issued at NZ$0.17 per share, with over 93% of capital coming from existing shareholders.
SPH Notice - Harbour Asset Management Limited
Harbour Asset Management Limited changed substantial holding from 9.957% to 11.144%.
Retail Offer to Close 28 May 2026; Likely to be Scaled
Pacific Edge (NZX/ASX: PEB), a cancer diagnostics company, announced that its retail share offer closing on 28 May 2026 has received NZ$14.0 million in applications against a target of NZ$6 million, making scaling of applications likely. Eligible shareholders who applied will have their allocations scaled back proportionally based on their shareholdings as of 8 May 2026.
Advancing Medicare Coverage Goals; Cost Contained
Pacific Edge Limited reported FY26 audited financial results showing an operating revenue of NZ$11.5 million (down 47.4% from FY25) due to Medicare coverage loss, with a net loss of NZ$35.8 million; however, the company achieved a significant strategic milestone post-balance date with Novitas publishing a draft Local Coverage Determination (LCD DL40378) establishing Medicare coverage for its Cxbladder Triage and Triage Plus tests for microhematuria patients, with Triage Plus priced at US$1,328 offering improved unit economics and a pathway to profitability.
D&O Disclosures - Multiple
Pacific Edge Limited directors disclosed multiple share transactions: Bryan Raymond George Williams acquired 237,647 ordinary shares for $40,400 on 15-May-26 as part of a placement, and director Anatole Masfen sold 1,000,000 shares at $0.10 per share on 9-Sept-25 and purchased 10,579,950 shares at $0.17 per share on 13-Aug-25 through Opito Trust for $1,798,591.50.
SPH Notice - ANZ New Zealand Investments Limited
ANZ New Zealand Investments Limited changed substantial holding from 16.599% to 18.221%.
Get real-time alerts for PEB
Receive AI-powered earnings summaries and instant notifications when Pacific Edge Limited Ordinary Shares releases results.
Register Free